DaVita (NYSE:DVA) Stock Rating Raised to Buy at Wall Street Zen

Wall Street Zen upgraded shares of DaVita (NYSE:DVA) from a hold rating to a buy rating in a research note released on Saturday,Wall Street Zen reports.

Several other equities research analysts also recently weighed in on DVA. Truist Financial reduced their price objective on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a report on Friday, August 7th. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. UBS Group raised their price objective on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Raymond James Financial set a $220.00 target price on DaVita in a report on Friday, August 7th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $233.43.

DaVita Trading Down 1.1%

NYSE DVA opened at $187.16 on Friday. DaVita has a 52 week low of $101.00 and a 52 week high of $247.49. The stock has a market cap of $11.94 billion, a P/E ratio of 15.32, a PEG ratio of 0.49 and a beta of 0.80. The company’s fifty day simple moving average is $180.47 and its 200-day simple moving average is $190.56.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same quarter in the previous year, the firm earned $2.95 earnings per share. The business’s revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts expect that DaVita will post 14.57 EPS for the current fiscal year.

Institutional Investors Weigh In On DaVita

Several hedge funds have recently made changes to their positions in DVA. Berkshire Hathaway Inc acquired a new stake in DaVita during the 2nd quarter valued at $6,425,269,000. BlackRock Inc. acquired a new stake in DaVita during the 2nd quarter worth about $547,520,000. Bank of America Corp DE purchased a new position in DaVita during the second quarter valued at approximately $145,057,000. Bank of New York Mellon Corp purchased a new position in shares of DaVita during the 2nd quarter valued at $101,127,000. Finally, Deutsche Bank AG bought a new stake in shares of DaVita in the 2nd quarter valued at approximately $46,356,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc is a healthcare company focused on kidney care and renal disease management. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with end-stage kidney disease, including hemodialysis and peritoneal dialysis, as well as home dialysis support.

The company also operates hospital-based dialysis programs and offers clinical, administrative and care-coordination services intended to support patients across the kidney-care journey.